![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
![[thumbnail of 15576oa.pdf]](https://mdc-test.eprints-hosting.org/style/images/fileicons/application_pdf.png) |
PDF
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
2MB |
| Item Type: | Article |
|---|---|
| Title: | Relaxin treatment in an Ang-II-based transgenic reeclamptic-rat model |
| Creators Name: | Haase, N., Golic, M., Herse, F., Rugor, J., Linz, D., Solano, M.E., Müller, D.N. and Dechend, R. |
| Abstract: | Relaxin is a peptide related to pregnancy that induces nitric oxide-related and gelatinase-related effects, allowing vasodilation and pregnancy-related adjustments permitting parturition to occur. Relaxin controls the hemodynamic and renovascular adaptive changes that occur during pregnancy. Interest has evolved regarding relaxin and a therapeutic principle in preeclampsia and heart failure. Preeclampsia is a pregnancy disorder, featuring hypertension, proteinuria and placental anomalies. We investigated relaxin in an established transgenic rat model of preeclampsia, where the phenotype is induced by angiotensin (Ang)-II production in mid pregnancy. We gave recombinant relaxin to preeclamtic rats at day 9 of gestation. Hypertension and proteinuria was not ameliorated after relaxin administration. Intrauterine growth retardation of the fetus was unaltered by relaxin. Heart-rate responses and relaxin levels documented drug effects. In this Ang-II-based model of preeclampsia, we could not show a salubrious effect on preeclampsia. |
| Keywords: | Angiotensins, Animal Disease Models, Fetal Growth Retardation, Pre-Eclampsia, Pregnancy, Relaxin, Transgenic Rats, Animals, Rats |
| Source: | PLoS ONE |
| ISSN: | 1932-6203 |
| Publisher: | Public Library of Science |
| Volume: | 11 |
| Number: | 3 |
| Page Range: | e0150743 |
| Date: | 10 March 2016 |
| Official Publication: | https://doi.org/10.1371/journal.pone.0150743 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
